Edit |   |
Antigenic Specificity | Heparan Sulfate Proteoglycan (Large) / Perlecan |
Clone | [SPM255] |
Host Species | Rat |
Reactive Species | human, monkey, cow, porcine, mouse, fish |
Isotype | IgG2a, kappa |
Format | unconjugated |
Size | 0.02 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (Without BSA at 1mg/ml) |
Concentration | n/a |
Applications | Flow Cytometry (FC/FACS), Immunofluorescence (IF), Immunohistochemistry (IHC) Formalin |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | This MAb specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecan s strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growt |
Immunogen | Immunogen: Murine EHS laminin preparation |
Other Names | [Heparan sulfate proteoglycan of basement membrane; HSPG; Hspg2; LG3 peptide; Perlecan; PLC; SJS1], [HSPG2; HSPG2; PLC; SJA; SJS; HSPG; SJS1; PRCAN; HSPG; PLC] |
Gene, Accession # | [HSPG2], Gene ID: 3339, NCBI: NP_001278789.1, UniProt: P98160 |
Catalog # | MBS439129 |
Price | $190, $340, $340 |
Order / More Info | Heparan Sulfate Proteoglycan (Large) / Perlecan Antibody from MYBIOSOURCE INC. |
Product Specific References | Folkvord et. al., J Histochem Cytochem, 1989; 37:105-113. Couchman et. al., Matrix, 1989; 9:311-321. Horiguchi et. al., J Histochem Cytochem, 1989; 37:961-970. Ljubimov et. al., Int J Cancer, 1992; 50:562-566. Guelstein et. al., Int J Cancer, 1993; 53:269-277. Ljubimov et. al., Lab Invest, 1995; 72:461-473. |